^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Free radical stimulant

    Related drugs:
    19d
    NCI-2020-03731: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Hensify (crystalline hafnium oxide)
    1m
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial primary completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    2ms
    Efficacy and safety of artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in South Sudan. (ACTRN12626000495325)
    P4, N=440, Completed, Ministry of Health
    New P4 trial
    2ms
    Evaluation of the Efficacy and Safety of HM001 for the Treatment of Moderate to Severe Cancer Pain: An Exploratory, Single-Arm, Open, Single-Center Study (ChiCTR2600120501)
    P1, N=30, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New P1 trial
    2ms
    A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer (ChiCTR2600118958)
    P2, N=130, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Canc
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab) • Hensify (crystalline hafnium oxide)
    2ms
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hensify (crystalline hafnium oxide)
    3ms
    NCI-2020-03731: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    Hensify (crystalline hafnium oxide)
    3ms
    Multi-omics network pharmacology and computational validation reveal amodiaquine and desethylamodiaquine as apoptosis-regulating multi-target candidates in colon adenocarcinoma. (PubMed, Comput Biol Chem)
    These results suggest that amodiaquine derivatives have anti-COAD actions due to their disruption of important immune-regulatory and apoptotic pathways. These findings computationally prioritize amodiaquine and desethylamodiaquine as candidate multi-target interactors in colon adenocarcinoma, warranting further experimental investigation rather than implying established therapeutic efficacy.
    Journal
    |
    SYK (Spleen tyrosine kinase) • KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2)
    3ms
    APP: A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, University of Oxford
    New P1 trial
    4ms
    90301900HNC1001: A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC (2025-522914-22-00)
    P1, N=8, Recruiting, Janssen Cilag International
    New P1 trial
    |
    Hensify (crystalline hafnium oxide)
    4ms
    Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Hensify (crystalline hafnium oxide)
    4ms
    OPTIMAH: OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (clinicaltrials.gov)
    P4, N=380, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open